It is plausible to speculate that TRPC3 inhibition might be instrumental in blocking excessive renal water retention during the clinically relevant states associated high AVP levels, such as congestive heart failure or syndrome of inappropriate AVP secretion [1]. This evidence concerns the gene AVP and congestive heart failure.